Navigation Links
TGen finds protein inhibitor revives chemotherapy for ovarian patients
Date:7/6/2010

nations that go after preventing cancer cells to repair themselves, in the clinic already, and we have seen early exciting results. Patients whose tumors had stopped responding to conventional chemotherapy have been made sensitive again, meaning some of these patients responded again to the chemotherapy. The importance of the paper is that it provides evidence that combinations of cisplatin and CHEK1 inhibitors may be worthwhile pursuing in patients with ovarian cancer," said Dr. Tibes.

TCRS is a partnership between TGen and Scottsdale Healthcare that enables laboratory discoveries to be quickly translated into effective therapies for patients at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

For this research, TGen investigators used cutting-edge technology to screen 572 kinases, the body's protein enzymes that affect how cells function. They discovered 55 siRNAs strands of RNA molecules that affect the expression of genes that to some degree enabled cisplatin to slow the growth of cancer cells.

According to the paper, one of those small molecule inhibitors, PD 407824, was especially effective in sensitizing ovarian cancer cells, SKOV3 and OVCAR3, to the growth inhibiting effects of cisplatin. PD 407824 and SB 218078 were the two small molecule inhibitors to CHEK1, that were found to sensitize pancreatic cancer cells to the chemotherapy drug gemcitabine, according to a paper published by the same group last year in the Journal of Translational Medicine.

"Our new data provide kinase targets that could be exploited to design better therapeutics for ovarian cancer patients," said Dr. David Azorsa, Head of TGen's Biological Therapeutics Lab and the senior author of the paper published in Gynecologic Oncology.

In addition, Shilpi Arora, a TGen Staff Scientist and the paper's lead author, said this data, "also demonstrate the effectiveness of high-throughput RNAi screening as a tool for identifying se
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. Terrorist de-radicalization shows promise, comprehensive study finds
2. Air pollution doesnt increase risk of preeclampsia, early delivery, study finds
3. Study finds that simple 2-question survey can better identify hungry children
4. Messenger RNAs are regulated in far more ways than previously appreciated, CSHL team finds
5. Organic pesticides not always greener choice, study finds
6. NIH-supported study finds novel pathway may open doors for new blood pressure treatments
7. Large majority of Americans still believe in global warming, Stanford poll finds
8. Study finds epigenetic similarities between Wilms tumor cells and normal kidney stem cells
9. UM School of Medicine study finds vaginal microbes vary among healthy women
10. Neural tissue contains imbalanced levels of proteins, U-M study finds
11. Jumping genes provide extensive raw material for evolution, Penn study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... (May 17, 2013) Illustrating a commitment to ... American Gastroenterological Association (AGA) Research Foundation has announced ... Research Fellowship Award recipients. Supported by the National ... (NIDDK), this new award helps underrepresented minority students ... and nutrition research. , "By establishing this new ...
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... Developmental Biology (SDB) 72nd Annual Meeting in Cancun, ... meant to promote the entry of students, postdoctorates ... of the basic science community and to encourage ... 2013 Annual Meeting. , Awards are given to ...
(Date:5/16/2013)... the stability of today,s largest ice sheets in Greenland and ... ago, for example when Earth was going through a ... high sea level due to ice sheet collapse at that ... if the world,s largest ice sheets collapsed in the past, ... progressively warming world. , However, a new groundbreaking study ...
Breaking Biology News(10 mins):Underrepresented minority students receive fellowships in digestive disease and nutrition research 2World's biggest ice sheets likely more stable than previously believed 2
... Autism Speaks, the nation,s largest autism science and advocacy ... to investigate genetic and environmental risk factors for autism. ... multi-site studies focusing on a collaborative prospective study of ... who are at higher genetic risk for developing the ...
... legs learned to walk upright. So did Faith, ... "half-man" born without legs, grew naturally into a graceful hand-walker. ... Hensel live successfully with separate heads connected to a single ... to drive, swim, shuffle cards and play piano. In ...
... that modern lifestyle habits may play a bigger role than ... A review of the scientific evidence over the past 150 ... hygiene and health education, may override the effects of food ... a Supplement to the journal Obesity Reviews . ...
Cached Biology News:Autism Speaks funds $5 million to studies on genetic and environmental risk factors for autism 2Autism Speaks funds $5 million to studies on genetic and environmental risk factors for autism 3Autism Speaks funds $5 million to studies on genetic and environmental risk factors for autism 4Autism Speaks funds $5 million to studies on genetic and environmental risk factors for autism 5'Freaks' help scientist unravel nature and nurture 2'Freaks' help scientist unravel nature and nurture 3
(Date:5/17/2013)... provider of scientific, technical and medical information products and ... in Reproductive BioMedicine Online on ... abnormal chromosomal composition can be identified by the rate ... the risk of genetic abnormality without a biopsy. In ... retrospective study, using their predictive model to assess the ...
(Date:5/17/2013)... May 17, 2013 New ... most innovative thought leaders of the medical device ... East conference and expo, from June 18-20 in ... (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) , ... deliver industry professionals practical presentations and implementable solutions ...
(Date:5/17/2013)... May 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased ... with Switzerland -based Kenta Biotech ... monoclonal antibody (mAb) products, and technologies. This asset ... for treatment of infections by common pathogens including ... , Pseudomonas aeruginosa , Acinetobacter baumannii ...
(Date:5/17/2013)... May 17, 2013 The paradigm of ... biological systems that can help predict the adverse and ... Sergey Stepaniants, Head of Computational Biology at the Genomics ... tools to ensure high-quality genomics when used as part ... applied to complex data sets to identify key clinical ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... Milestone Validates Approach, SAN FRANCISCO, January 22 ... its first clinical trial, a,proof-of-concept study that evaluated ... blocker. Rufinamide was discovered and,developed by Novartis and ... a,drug to treat a form of epilepsy. This ...
... B.V. announced today the closure of its Series ... Ventures., Progentix Orthobiology B.V. was established in ... products for clinical application,in bone regenerative surgery. Progentix ... biomaterial scaffolds that have the ability to,attract growth ...
... NorTech Venture,Capital Advisory Task Force reported in its inaugural ... generate and attract over $1.2 billion,in venture capital by ... companies,located in Northeast Ohio. According to the findings from ... region, to be,released in print mid February, Northeast Ohio ...
Cached Biology Technology:Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 2Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 3Progentix Orthobiology B.V. Closes Series A Financing Round 2Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 2Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 3Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 4Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 5
Candida (IgG) -Ab EIA Sample Size: 5 l...
... Oxidized LDL (Competitive) EIA Principle: ... the monoclonal antibody 4E6. Oxidized LDL in the ... LDL bound to the microtiter well for the ... a washing st Sample Size: 25 ...
... RNase III, used with its manganese-containing reaction ... heterogeneous mix of short (1825 bp) interfering ... mammalian cells. 1.3 units (1 l) of ... 1 g of dsRNA into siRNA suitable ...
For cleavage of 6xHis tags from proteins containing a Factor Xa Protease recognition site Efficient 6xHis tag cleavage (greater than 90%), ...
Biology Products: